SWM
CNTA

Spire Wealth Management’s Centessa Pharmaceuticals CNTA Stock Holding History

Spire Wealth Management’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-70
Closed -$632 – 2181
2024
Q2 		$632 Hold
70
– – ﹤0.01% 2171
2024
Q1 		$791 Hold
70
– – ﹤0.01% 2239
2023
Q4 		$567 Buy
+70
New +$469 ﹤0.01% 2347

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Spire Wealth Management's CNTA Position: Q3 2024 in Review

Spire Wealth Management sold out of Centessa Pharmaceuticals (CNTA) in Q3 2024, closing a stake of 70 shares — an estimated $632 sold.

Spire Wealth Management first reported a position in CNTA in Q4 2023 and held it in 3 quarters. The position peaked at $791 in Q1 2024. 103 funds tracked by Wall St. Rank hold CNTA as of Q3 2024.

  • Spire Wealth Management reported no remaining Centessa Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Spire Wealth Management sold 70 Centessa Pharmaceuticals shares in Q3 2024, an estimated $632.
  • Spire Wealth Management first reported a position in Centessa Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Spire Wealth Management's Centessa Pharmaceuticals position peaked at $791 in Q1 2024.
  • 103 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q3 2024.

Based on Spire Wealth Management's 13F filing for Q3 2024, filed 15 Oct 2024.